BridgeBio Pharma (BBIO) Competitors

$68.61 +2.66 (+4.03%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$68.60 0.00 (-0.01%)

As of 05/13/2026 07:58 PM Eastern

BBIO vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy BridgeBio Pharma stock or one of its competitors? MarketBeat compares BridgeBio Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Pharma include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

BridgeBio Pharma (NASDAQ:BBIO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.76	-$724.93M	-$3.74	N/A
Takeda Pharmaceutical	$30.09B	1.76	$712.33M	$0.24	69.27

In the previous week, BridgeBio Pharma had 38 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 44 mentions for BridgeBio Pharma and 6 mentions for Takeda Pharmaceutical. BridgeBio Pharma's average media sentiment score of 0.41 beat Takeda Pharmaceutical's score of -0.21 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	12 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

BridgeBio Pharma presently has a consensus price target of $88.19, indicating a potential upside of 28.54%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Takeda Pharmaceutical has a net margin of 2.58% compared to BridgeBio Pharma's net margin of -124.42%. Takeda Pharmaceutical's return on equity of 10.60% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Takeda Pharmaceutical	2.58%	10.60%	5.21%

Summary

BridgeBio Pharma beats Takeda Pharmaceutical on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to argenex?

argenex (NASDAQ:ARGX) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

In the previous week, BridgeBio Pharma had 16 more articles in the media than argenex. MarketBeat recorded 44 mentions for BridgeBio Pharma and 28 mentions for argenex. argenex's average media sentiment score of 0.72 beat BridgeBio Pharma's score of 0.41 indicating that argenex is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	8 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	12 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

argenex currently has a consensus price target of $1,017.78, suggesting a potential upside of 26.79%. BridgeBio Pharma has a consensus price target of $88.19, suggesting a potential upside of 28.54%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92

argenex has a net margin of 31.31% compared to BridgeBio Pharma's net margin of -124.42%. argenex's return on equity of 33.28% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
BridgeBio Pharma	-124.42%	N/A	-65.81%

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.75	$1.29B	$22.46	35.74
BridgeBio Pharma	$502.08M	26.76	-$724.93M	-$3.74	N/A

60.3% of argenex shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

argenex beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries (NYSE:TEVA) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 31 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 44 mentions for BridgeBio Pharma and 13 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.67 beat BridgeBio Pharma's score of 0.41 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teva Pharmaceutical Industries	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	12 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BridgeBio Pharma's net margin of -124.42%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, suggesting a potential upside of 15.22%. BridgeBio Pharma has a consensus price target of $88.19, suggesting a potential upside of 28.54%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92

Teva Pharmaceutical Industries has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teva Pharmaceutical Industries	$17.26B	2.42	$1.41B	$1.33	27.26
BridgeBio Pharma	$502.08M	26.76	-$724.93M	-$3.74	N/A

Summary

Teva Pharmaceutical Industries and BridgeBio Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

BeOne Medicines has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 28 more articles in the media than BeOne Medicines. MarketBeat recorded 44 mentions for BridgeBio Pharma and 16 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 0.51 beat BridgeBio Pharma's score of 0.41 indicating that BeOne Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	5 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	12 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

BeOne Medicines has a net margin of 8.94% compared to BridgeBio Pharma's net margin of -124.42%. BeOne Medicines' return on equity of 12.06% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
BridgeBio Pharma	-124.42%	N/A	-65.81%

BeOne Medicines currently has a consensus price target of $391.00, suggesting a potential upside of 23.52%. BridgeBio Pharma has a consensus price target of $88.19, suggesting a potential upside of 28.54%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than BeOne Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.79
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92

BeOne Medicines has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.50	$286.93M	$4.47	70.82
BridgeBio Pharma	$502.08M	26.76	-$724.93M	-$3.74	N/A

Summary

BeOne Medicines beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Revolution Medicines?

BridgeBio Pharma (NASDAQ:BBIO) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

BridgeBio Pharma currently has a consensus price target of $88.19, suggesting a potential upside of 28.54%. Revolution Medicines has a consensus price target of $103.88, suggesting a potential downside of 30.72%. Given BridgeBio Pharma's higher probable upside, equities research analysts plainly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	0 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.92
Revolution Medicines	1 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	3.10

BridgeBio Pharma has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.41, suggesting that its share price is 41% more volatile than the broader market.

In the previous week, BridgeBio Pharma had 23 more articles in the media than Revolution Medicines. MarketBeat recorded 44 mentions for BridgeBio Pharma and 21 mentions for Revolution Medicines. BridgeBio Pharma's average media sentiment score of 0.41 beat Revolution Medicines' score of 0.19 indicating that BridgeBio Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	12 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Revolution Medicines	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 8.2% of Revolution Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Revolution Medicines	N/A	-83.22%	-59.06%

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	26.76	-$724.93M	-$3.74	N/A
Revolution Medicines	$11.58M	2,752.78	-$1.13B	-$7.07	N/A

Summary

BridgeBio Pharma beats Revolution Medicines on 11 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.92B	$5.96B	$6.30B	$12.20B
Dividend Yield	N/A	0.70%	2.79%	5.30%
P/E Ratio	-18.34	7.58	20.99	25.65
Price / Sales	26.76	23.88	555.98	78.93
Price / Cash	N/A	8.03	42.94	55.34
Price / Book	-5.92	4.34	9.70	6.66
Net Income	-$724.93M	$118.49M	$3.55B	$333.63M
7 Day Performance	1.72%	-0.98%	-0.56%	-0.11%
1 Month Performance	-11.96%	2.95%	1.17%	3.94%
1 Year Performance	103.83%	137.19%	41.20%	36.07%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.4435 of 5 stars	$68.61 +4.0%	$88.19 +28.5%	+106.3%	$12.92B	$502.08M	N/A	400	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
TAK Takeda Pharmaceutical	1.0322 of 5 stars	$16.57 -0.3%	N/A	+21.1%	$52.89B	$30.09B	69.02	47,455	News Coverage Gap Down
ARGX argenex	4.6438 of 5 stars	$811.09 +3.5%	$1,016.22 +25.3%	+48.0%	$48.72B	$4.25B	41.55	1,863	Earnings Report Analyst Revision
TEVA Teva Pharmaceutical Industries	4.0893 of 5 stars	$35.36 +1.2%	$41.56 +17.5%	+107.4%	$40.19B	$17.26B	26.58	33,950
ONC BeOne Medicines	4.2747 of 5 stars	$297.14 +1.1%	$390.58 +31.4%	+40.9%	$32.24B	$5.34B	117.91	12,000	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. TAK, ARGX, TEVA, ONC, and RVMD

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Summary

How does BridgeBio Pharma compare to argenex?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. TAK, ARGX, TEVA, ONC, and RVMD

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Which has more risk and volatility, BBIO or TAK?

Which has stronger earnings & valuation, BBIO or TAK?

Does the media refer more to BBIO or TAK?

Do analysts prefer BBIO or TAK?

Do insiders and institutionals have more ownership in BBIO or TAK?

Is BBIO or TAK more profitable?

Summary

How does BridgeBio Pharma compare to argenex?

Which has more volatility and risk, ARGX or BBIO?

Does the media prefer ARGX or BBIO?

Do analysts recommend ARGX or BBIO?

Is ARGX or BBIO more profitable?

Which has preferable valuation & earnings, ARGX or BBIO?

Do institutionals and insiders hold more shares of ARGX or BBIO?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Which has more volatility and risk, TEVA or BBIO?

Do institutionals and insiders hold more shares of TEVA or BBIO?

Does the media prefer TEVA or BBIO?

Is TEVA or BBIO more profitable?

Do analysts recommend TEVA or BBIO?

Which has preferable valuation & earnings, TEVA or BBIO?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Which has more volatility & risk, ONC or BBIO?

Do insiders & institutionals hold more shares of ONC or BBIO?

Does the media favor ONC or BBIO?

Is ONC or BBIO more profitable?

Do analysts recommend ONC or BBIO?

Which has better valuation and earnings, ONC or BBIO?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Do analysts prefer BBIO or RVMD?

Which has more risk & volatility, BBIO or RVMD?

Does the media favor BBIO or RVMD?

Do institutionals & insiders hold more shares of BBIO or RVMD?

Is BBIO or RVMD more profitable?

Which has preferable valuation & earnings, BBIO or RVMD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools